Provided by Tiger Trade Technology Pte. Ltd.

Axsome Therapeutics

204.76
+6.243.14%
Volume:213.70K
Turnover:43.35M
Market Cap:10.73B
PE:-54.33
High:204.97
Open:199.71
Low:199.71
Close:198.52
52wk High:260.19
52wk Low:112.90
Shares:52.38M
Float Shares:43.83M
Volume Ratio:0.67
T/O Rate:0.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7685
EPS(LYR):-3.6821
ROE:-245.10%
ROA:-16.31%
PB:128.75
PE(LYR):-55.61

Loading ...

Axsome Therapeutics Facing 'Attractive Setup' Ahead of Auvelity's Label Expansion Decision, Oppenheimer Says

MT Newswires Live
·
Apr 21

Axsome Therapeutics Is Maintained at Buy by UBS

Dow Jones
·
Apr 11

Axsome Therapeutics Upside Tied to Auvelity FDA Decision, $2 Billion Sales Opportunity Seen, UBS Says

MT Newswires Live
·
Apr 10

UBS Adjusts Axsome Therapeutics Price Target to $259 From $251, Maintains Buy Rating

MT Newswires Live
·
Apr 10

Jefferies Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)

TIPRANKS
·
Apr 09

Axsome Therapeutics: Auvelity’s Best‑in‑Class Potential in Alzheimer’s Agitation Supports Buy Rating

TIPRANKS
·
Apr 09

Axsome Therapeutics to report first-quarter results, host conference call

Reuters
·
Apr 08

Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4

GlobeNewswire
·
Apr 08

RBC Capital Adjusts Price Target on Axsome Therapeutics to $221 From $222, Maintains Outperform Rating

MT Newswires Live
·
Apr 07

Analysts Offer Insights on Healthcare Companies: Imunon (IMNN), Axsome Therapeutics (AXSM) and Oric Pharmaceuticals (ORIC)

TIPRANKS
·
Apr 02

BUZZ-U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences

Reuters
·
Apr 02

BUZZ-U.S. STOCKS ON THE MOVE-Seagate, nCino, Zymeworks

Reuters
·
Apr 01

Axsome buys global rights to Takeda schizophrenia drug candidate balipodect (TAK-063)

Reuters
·
Apr 01

Axsome Therapeutics Inc - to Begin Phase 3 Trial-Enabling Activities for Schizophrenia in 2026

THOMSON REUTERS
·
Apr 01

Axsome Therapeutics Inc - Obtains Exclusive Global Rights to Balipodect From Takeda

THOMSON REUTERS
·
Apr 01

Axsome Therapeutics Inc - Takeda Receives Upfront Payment, Eligible for Milestone Payments and Royalties

THOMSON REUTERS
·
Apr 01

Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions

GlobeNewswire
·
Apr 01

Axsome Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
Mar 25

Axsome Therapeutics price target raised to $245 from $220 at Guggenheim

TIPRANKS
·
Mar 25

Axsome Still Offers 'Compelling' Core Story, RBC Says

MT Newswires Live
·
Mar 14